Alphamab Oncology (HKSE:09966) Cash-to-Debt : 5.47 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Alphamab Oncology's cash to debt ratio for the quarter that ended in Dec. 2023 was 5.47.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Alphamab Oncology could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Alphamab Oncology's Cash-to-Debt or its related term are showing as below:

HKSE:09966' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.12 Med: 5.71 Max: No Debt
Current: 5.47

During the past 7 years, Alphamab Oncology's highest Cash to Debt Ratio was No Debt. The lowest was 3.12. And the median was 5.71.

HKSE:09966's Cash-to-Debt is ranked worse than
53.22% of 1492 companies
in the Biotechnology industry
Industry Median: 6.85 vs HKSE:09966: 5.47

Alphamab Oncology Cash-to-Debt Historical Data

The historical data trend for Alphamab Oncology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Alphamab Oncology Cash-to-Debt Chart

Alphamab Oncology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

9.41

9.27

3.12

3.91

5.47

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial								3.12	3.25	3.91	5.58	5.47

Competitive Comparison of Alphamab Oncology's Cash-to-Debt

For the Biotechnology subindustry, Alphamab Oncology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alphamab Oncology's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's Cash-to-Debt falls into.

Alphamab Oncology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Alphamab Oncology's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1539.205	/	(88.047	+	193.142)
	=	5.47

Alphamab Oncology's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1539.205	/	(88.047	+	193.142)
	=	5.47

Alphamab Oncology (HKSE:09966) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Alphamab Oncology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology (HKSE:09966) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

3NK:Germany

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215024

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.

Executives

South Dakota Trust Company Llc	2301 Trustee
Xu Ting	2305 Beneficiary of a trust
Liu Yang	2307 Founder of a discretionary trust who can infl
Rubymab Ltd.	2101 Beneficial owner
Pang Kee Chan Hebert
Highbury Investment Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Advantech Capital Ii Investment Partners Limited
Advantech Capital Ii Alphamab Partnership L.p.
Advantech Capital Partners Ii Limited
Advantech Capital Investment I Limited
Advantech Capital Ii Master Investment Limited
Advantech Capital Ii L.p.

Alphamab Oncology (HKSE:09966) Headlines

No Headlines